Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 1
2020 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients.
Ungaro R, Taramasso L, Bruzzone B, Vicenti I, Galli L, Borghi V, Francisci D, Pecorari M, Zoncada A, Callegaro AP, Paolini E, Monno L, Bonora S, Di Biagio A; ARCA Study Group. Ungaro R, et al. Clin Microbiol Infect. 2019 Nov;25(11):1443-1446. doi: 10.1016/j.cmi.2019.07.004. Epub 2019 Jul 25. Clin Microbiol Infect. 2019. PMID: 31352080 Free article. No abstract available.
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D'Avino A, Focà E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A; ATLAS-M Study Group. Fabbiani M, et al. J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123. J Antimicrob Chemother. 2018. PMID: 29668978 Clinical Trial.
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study.
Gagliardini R, Ciccullo A, Borghetti A, Maggiolo F, Bartolozzi D, Borghi V, Pecorari M, Di Biagio A, Callegaro AP, Bruzzone B, Saladini F, Paolucci S, Maserati R, Zazzi M, Di Giambenedetto S, De Luca A; ARCA Study Group. Gagliardini R, et al. Open Forum Infect Dis. 2018 May 15;5(6):ofy113. doi: 10.1093/ofid/ofy113. eCollection 2018 Jun. Open Forum Infect Dis. 2018. PMID: 29977967 Free PMC article.
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
Rusconi S, Adorni F, Tau P, Borghi V, Pecorari M, Maserati R, Francisci D, Monno L, Punzi G, Meraviglia P, Paolucci S, Di Biagio A, Bruzzone B, Mancon A, Micheli V, Zazzi M; ARCA (Antiviral Response Cohort Analysis). Rusconi S, et al. J Clin Virol. 2018 Aug;105:112-117. doi: 10.1016/j.jcv.2018.06.012. Epub 2018 Jun 21. J Clin Virol. 2018. PMID: 29957545